Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant

H. Ling*†‡, R. de Silva*†‡, L. A. Massey*†, R. Courtney*†, G. Hondhamuni*†, N. Bajaj§, J. Lowe¶, J. L. Holton*†‡, A. Lees*†‡ and T. Revesz*†‡

*Reta Lila Weston Institute of Neurological Studies, †Queen Square Brain Bank for Neurological Disorders and §Sara Koe PSP Research Centre, Institute of Neurology, University College London, London, ¶Department of Clinical Neurology, Nottingham University Hospitals NHS Trust, and ‡Department of Pathology, Queen’s Medical Centre, University of Nottingham, Nottingham, UK

H. Ling, R. de Silva, L. A. Massey, R. Courtney, G. Hondhamuni, N. Bajaj, J. Lowe, J. L. Holton, A. Lees and T. Revesz (2014) Neuropathology and Applied Neurobiology 40, 149–163

Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant

Aims: Since the first description of the classical presentation of progressive supranuclear palsy (PSP) in 1963, now known as Richardson’s syndrome (PSP-RS), several distinct clinical syndromes have been associated with PSP-tau pathology. Like other neurodegenerative disorders, the severity and distribution of phosphorylated tau pathology are closely associated with the clinical heterogeneity of PSP variants. PSP with corticobasal syndrome presentation (PSP-CBS) was reported to have more tau load in the mid-frontal and inferior-parietal cortices than in PSP-RS. However, it is uncertain if differences exist in the distribution of tau pathology in other brain regions or if the overall tau load is increased in the brains of PSP-CBS.

Methods: We sought to compare the clinical and pathological features of PSP-CBS and PSP-RS including quantitative assessment of tau load in 15 cortical, basal ganglia and cerebellar regions.

Results: In addition to the similar age of onset and disease duration, we demonstrated that the overall severity of tau pathology was the same between PSP-CBS and PSP-RS. We identified that there was a shift of tau burden towards the cortical regions away from the basal ganglia: supporting the notion that PSP-CBS is a ‘cortical’ PSP variant. PSP-CBS also had less severe neuronal loss in the dorsolateral and ventrolateral subregions of the substantia nigra and more severe microglial response in the corticospinal tract than in PSP-RS; however, neuronal loss in subthalamic nucleus was equally severe in both groups.

Conclusions: A better understanding of the factors that influence the selective pathological vulnerability in different PSP variants will provide further insights into the neurodegenerative process underlying tauopathies.

Keywords: alien limb, corticobasal syndrome, progressive supranuclear palsy, Richardson’s syndrome, tau

Introduction

The classical presentation of progressive supranuclear palsy (PSP), now known as Richardson’s syndrome (PSP-RS), includes as cardinal features the early onset of postural instability with falls backwards, vertical supranuclear gaze palsy (VSGP) including downgaze and frontal subcortical cognitive impairment [1–3]. Other well-recognized clinical variants of PSP are PSP-parkinsonism...
Clinicopathological studies have since demonstrated a close correlation between topographical severity of tau pathology and clinical phenotypes of PSP. For instance, severe tau pathology was identified in the inferior frontal gyrus in PSP-PNFA and frontal and temporal cortices in PSP-bvFTD. In contrast, cortical tau was found to be very mild in the PSP-PAGF subtype. Similar clinicopathological correlation was also identified in another closely related 4-repeat (4R) tauopathy, corticobasal degeneration (CBD) and its clinical phenotypes.

Corticobasal syndrome (CBS) describes progressive clumsiness and loss of function of one hand due to apraxia, an alien limb, cortical sensory loss, dystonia and levodopa-unresponsive rigidity, and it was initially described as the distinctive clinical presentation of CBD. Since its original description, multifarious other pathologies have been linked to a CBS presentation. From the archives of the Queen Square Brain Bank for Neurological Disorders (QSBB), we showed that the most common underlying pathology for CBS is PSP (6 of 21) rather than CBD (5 of 21); however, only 4% of all CBS cases are PSP. An additional case, seen and diagnosed pathologically at the University of Nottingham, was also included. These 10 PSP-CBS cases were matched with 10 PSP-RS control cases for disease duration and age at death. The brain donor programme of the QSBB was approved by a London Multi-Centre Research Ethics Committee and tissue is stored for research under a license from the Human Tissue Authority.

Materials and methods

Cases

Of the 227 PSP cases available in the QSBB archives between 1988 and 2010, nine had received a final clinical diagnosis of CBS/CBD by a neurologist during life (PSP-CBS, 3.9% of all PSP cases). An additional case, seen and diagnosed pathologically at the University of Nottingham, was also included. These 10 PSP-CBS cases were matched with 10 PSP-RS control cases for disease duration and age at death. The brain donor programme of the QSBB was approved by a London Multi-Centre Research Ethics Committee and tissue is stored for research under a license from the Human Tissue Authority.

Medical record review

Systematic retrospective review of the medical records was carried out by one of us (H. L.). All patients were assessed by at least one neurologist during life. Symptoms and clinical signs were recorded as being absent if they were not reported in the case notes. When the onset was not recorded, the onset was taken as the time when the particular clinical feature was first mentioned in the notes. If there were conflicting clinical features, the findings of the neurologist took precedence. The definitions for each selected clinical feature have been described previously.

Pathological material

The neuropathological diagnosis of PSP was confirmed in all 20 cases (T. R. and J. L. H.). Immediately after post mortem the brains were divided in the mid-sagittal plane. One half, chosen randomly, was sliced and tissue blocks were frozen and stored at −80°C, while the other half was...
immersed and fixed in 10% neutral formalin for 3 weeks before neuropathological examination. Tissue blocks were taken using standard protocols. Established pathological diagnostic criteria for PSP were used, requiring the presence of neurofibrillary tangles (NFTs), neuropil threads (NTs) and glial tau pathology in different brain regions including the cerebral cortex, striatum, globus pallidus (GP), subthalamic nucleus (STN), midbrain,pons and cerebellum together with neuronal loss and gliosis in basal ganglia and brainstem and cerebellar nuclei [20–23]. In each case 8-μm-thick tissue sections cut from the paraffin blocks and stained with haematoxylin and eosin (H&E) were used to assess neuronal loss and gliosis in the basal ganglia and substantia nigra. Immunohistochemistry with antibodies to phosphorylated tau (AT8; BioScience Life Sciences; 1:600), 3-repeat (3R) tau and 4R tau (Upstate/Millipore; 3R tau: RD3; 1:2000; 4R tau: RD4; 1:200) [24], microglia (CD68; Dako; PG-M1; 1:75), αB-crystallin (Novocastra; G2JF; 1:300), amyloid-β (Aβ) peptide (Dako; 6F/3D; 1:100) and α-synuclein (Vector Laboratories; KM51; 1:50) was performed using a standard avidin-biotin method as previously described [25].

Additional pathologies were documented. Argyrophilic grain disease was identified by AT8 and αB-crystallin immunohistochemistry [26] while Aβ cortical plaque pathology was characterized using the modified CERAD (Consortium to Establish a Registry for Alzheimer’s disease) criteria [27]. Alzheimer’s type NFT pathology was determined using AT8 immunohistochemistry for Braak and Braak staging [28]. The presence of incidental Lewy body disease [29], cerebrovascular disease [30] and cerebral amyloid angiopathy (CAA) [31] was documented. Only cases with limited Alzheimer-type neurofibrillary tangle pathology of Braak and Braak stage III or less were recruited to avoid confounding the analysis of PSP-related tau pathology.

Regional tau quantification with image analysis

Using coded slides, quantitative assessment of tau pathology, comprising all tau-positive structures including NFTs, pretangles (PreTs) NTs, tufted astrocytes (TAs) and coiled bodies (CBs) was performed by one rater (H. L.). Fifteen brain regions, which are known to be affected in PSP and whose involvement is predicted to contribute to the clinical features, were selected; the posterior frontal cortex including the motor strip, cerebral cortex and subcortical white matter of the middle frontal gyrus (level: 1 cm behind the temporal pole), middle temporal gyrus (level: mammillary body) and parietal region (level: 1 cm behind the splenium), caudate nucleus, putamen, GP, STN, substantia nigra (SN; level: emergence of the third cranial nerve), pontine base, including the pontine nuclei, cerebellar dentate nucleus and cerebellar white matter. The posterior frontal white matter was omitted from the analysis as the quantity was very small in some cases due to variability of routine sampling. In each region, the images of 10 random microscopic fields using a x20 objective were captured by a colour digital camera connected to the microscope (Nikon Microphot-FXA and Digit sight DS-L1) and processed with an image analysis software (Image-Pro; Media Cybernetics, Inc., Roper Industries, Rockville, USA), converted to grey-scale images and labelling was measured in pixels. Threshold was adjusted to capture the two-dimensional area of all tau-positive lesions and the same threshold setting was used throughout the study. ‘Areal fraction’, defined by a ratio of the tau-positive immunoreactive pixels to the total number of pixels of the whole field was computed by Image Pro and tau load for each region, that is, ‘regional’ tau load was expressed as percentage (areal fraction × 100%) [32]. ‘Total’ tau load was the sum of tau load in all 15 regions. ‘Cortical’ tau load was the sum of tau load in seven regions, comprised of both grey and subcortical white matter in the anterior frontal, temporal and parietal regions and grey matter in the posterior frontal region. ‘Basal ganglia’ tau load was the sum of tau load in four structures: caudate nucleus, putamen, GP and STN.

Quantification of tau-positive cellular lesions

The different tau-positive cellular lesions were quantified individually in 10 random fields of three selected regions (posterior frontal cortex, anterior frontal cortex and caudate), where differences in regional tau load were found to be the most robust between PSP-RS and PSP-CBS. NFTs, PreTs, TAs and CBs were individually counted. NT pathology was quantified using a four-tiered semi-quantitative grading scale (0–3, with grade 0 = no NT to grade 3 = most severe NT).

Neuronal loss in the subthalamic nucleus and substantia nigra

Neuronal loss in STN and SN were determined using a four-tiered semi-quantitative grading system by a neuropathologist (T. R.), blinded to the clinical features (0–3,
with grade 0 = no neuronal loss to grade 3 = most severe neuronal loss). SN was divided into five regions (medial, dorsomedial, dorsolateral, ventrolateral and lateral).

Corticospinal tract involvement

Microglial pathology of the corticospinal tract (CST) identified in the midbrain cerebral peduncles was assessed using CD68 immunohistochemistry by two neuropathologists (T. R. and J. H.) blinded to the clinical features. A semi-quantitative grade was established by consensus (grade 0 = baseline microglial population to grade 3 = most severe microglial pathology).

Tau biochemistry

Frontal cerebral cortex was used for tau biochemistry in two PSP-CBS, two PSP-RS cases and two pathologically diagnosed CBD cases with classical CBS presentation (CBD-CBS), which were randomly selected. Regional variation of phosphorylated tau species in PSP brains was previously reported [33]. However, tau protein extraction was limited to the frontal cortex in the present study.

Sarkosyl-insoluble tau isolation Isolation of sarkosyl-insoluble tau was carried out as previously described [34,35]. Brain tissue was homogenized in 10x volume (v/w) homogenization buffer (10 mM Tris–HCl pH 7.4, 0.8 M NaCl, 1 mM EGTA and 10% sucrose containing Complete protease inhibitor cocktail (Roche, Burgess Hill, UK). The suspension was then spun at 20 000 g for 20 min at 4°C and the supernatant set aside. The pellet was re-suspended in 5x volumes of homogenization buffer and re-centrifuged as above. The supernatants were combined and N-lauryl sarcosinate added to a concentration of 1% (w/v), and incubated at room temperature for 1 h with shaking. The mixture was then centrifuged at 100 000 g for 1 h at 4°C. The sarkosyl-insoluble pellet was re-suspended in 50 mM Tris–HCl pH 7.5 at 0.2 ml/g of starting material.

SDS-PAGE Sarkosyl-insoluble tau was separated on 10% SDS-polyacrylamide gels and blotted onto nitrocellulose membranes using standard procedures. The blots were probed with a pan-tau rabbit polyclonal TP70 antibody that recognizes the carboxy-terminus of tau [36,37] (1/15 000; kind gift from Dr Diane Hanger, King’s College, London) and IRDye 800CW Donkey Anti-Rabbit secondary antibody (Li-Cor Biosciences) followed by imaging on a Li-Cor Odyssey Infrared Scanner.

Haplotype analysis of the MAPT gene

Haplotype was determined by PCR (polymerase chain reaction) typing of the 238 bp MAPT H2 deletion in intron nine in 17 cases (8 PSP-CBS, 9 PSP-RS) where frozen tissue was available for DNA extraction [38,39].

Statistical analysis

The Mann–Whitney U-Test was used to compare tau load between PSP-CBS and PSP-RS. The null hypothesis (H0) was rejected if the P value was <0.05 when ‘total’, ‘cortical’ and ‘basal ganglia’ tau load was assessed. For ‘regional’ tau load assessment, P value of 0.0033 (0.05/15) was used to adjust for multiple comparisons; for tau-positive cellular lesion load, P value of 0.01 (5 different types of tau lesions: 0.05/5) was used. χ²/Fisher’s exact test or the Student’s t-test was used to compare semi-quantitative grading or clinical data using P value of 0.05. The intra-rater repeatability was assessed by repeating tau quantification in four randomly selected cases (20%). The intraclass correlation coefficient was 0.80 (P < 0.001), indicating that the ‘regional’ tau load results were highly repeatable. The spss 17.0 program (IBM Corporation, New York, USA) was used for statistical analysis.

Results

Clinical features

PSP-CBS (Tables 1a and 2) All patients had been diagnosed with CBS/CBD by neurologists during life. Mean duration of first symptom onset to the final clinical diagnosis was 3.4 years. All cases had strikingly asymmetrical clinical features throughout the entire disease course: 10 had ideomotor limb apraxia, eight had hand dystonia, five had focal distal myoclonus, three had an alien limb phenomenon, three had non-fluent aphasia, three had cortical sensory loss and wo had hemisensory neglect. Delayed initiation of horizontal saccades was observed in three patients, two of whom also had head thrust at saccadic initiation (cases 2 & 5).

Seven patients developed ocular features suggestive of PSP including slow vertical saccades or VSGP but in most
| Case no. | Gender | Age at onset (yr) | Age at death (yr) | Disease duration (yr) | Initial clinical Dx | Final clinical Dx | Duration from onset to final Dx (yr) | Initial symptom(s) | Asymmetrical features | Limb apraxia | Alien limb | Cortical sensory loss | Hemineglect | Aphasia | Hand dystonia | Clenched fist | Myoclonus | Tremor | Delayed initiation of saccades | Slow vertical saccades | VSGP | Postural instability/falls within 1st yr | Cognitive decline | Pyramidal signs | Akinetic rigidity in first 2 yrs | Dysarthria in first 2 yrs | Dysphagia in first 2 yrs | Levodopa response | H1/H2 Haplotype |
|---------|--------|------------------|------------------|----------------------|------------------|------------------|----------------------|-------------------|-------------------|------------|-----------|-------------------|------------|--------|--------------|-------------|--------|-------|------------------|------------------|------|------------------|---------------|-----------|-----------------|-----------------|--------------|------------------|----------------|-----------------|
| 1       | M      | 55               | 64.3             | 9.3                  | PD               | CBS              | 6.3                  | Balance difficulty | +                 | +         | +                  | -          | -      | +             | -            | -      | -     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |
| 2       | F      | 63.8             | 70.2             | 6.4                  | CBS              | CBS              | 3.5                  | Clumsy arm         | -                 | +         | +                  | -          | -      | -             | +            | -      | -     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |
| 3       | M      | 60.4             | 90               | 5.9                  | CBS              | CBS              | 5.2                  | Clumsy arm         | -                 | +         | +                  | -          | -      | -             | +            | -      | -     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |
| 4       | M      | 60.5             | 68.8             | 8.3                  | CBS              | CBS              | 2.1                  | Jerky arm          | +                 | +         | +                  | -          | -      | -             | +            | -      | -     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |
| 5       | M      | 79.3             | 82.8             | 3.5                  | PBS              | CBS              | 1.5                  | Falls              | -                 | +         | +                  | -          | -      | -             | -            | +      | +     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |
| 6       | F      | 66.3             | 77.9             | 11.6                 | Depression       | CBS              | 7                    | Gait difficulty & cognitive slowing | +   | +         | +                  | +          | -      | -             | -            | -      | -     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |
| 7       | F      | 60               | 70.8             | 10.8                 | CBS              | CBS              | 6                    | Falls              | -                 | +         | +                  | -          | -      | -             | -            | +      | +     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |
| 8       | F      | 64               | 72.5             | 8.5                  | CBS              | CBS              | 4                    | Balance difficulty & slurred speech | +   | +         | +                  | +          | -      | -             | -            | -      | -     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |
| 9       | F      | 77               | 81               | 4                    | CBS              | CBS              | 3                    | Clumsy useless arm & balance difficulty | -   | -         | -                  | -          | -      | -             | -            | -      | -     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |
| 10      | F      | 73               | 79.2             | 6.2                  | CBS              | CBS              | 3                    | -                   | -                 | -         | -                  | -          | -      | -             | -            | -      | -     | -                | -                | -    | -                | -              | -       | -                | -              | -      | -                | -              | -      |

Table 1a. Demographic, clinical and genetic haplotype data of PSP-CBS patients
### Table 1b. Demographic, clinical and genetic haplotype data of PSP-RS patients

| Case no. | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
|----------|----|----|----|----|----|----|----|----|----|----|
| Gender   | F  | F  | M  | M  | F  | M  | M  | F  | F  | M  |
| Age at onset (yr) | 62 | 65.2 | 63 | 74.3 | 66 | 61 | 52.1 | 67 | 72 | 76 |
| Age at death (yr) | 69.8 | 71.3 | 69.5 | 79.5 | 81.7 | 78.3 | 61.3 | 73 | 79.1 | 80.7 |
| Disease duration (yr) | 7.8 | 6.1 | 6.5 | 5.2 | 15.7 | 17.3 | 9.2 | 6 | 7.1 | 4.7 |
| Initial clinical Dx | Depression | PD | Depression | PD | PD | CVD | PSP | PSP | PSP | PSP |
| Final clinical Dx | PSP | PSP | PSP | PSP | PSP | PSP | PSP | PSP | PSP | PSP |
| Duration from onset to final Dx (yr) | 4 | 4 | 2.5 | 3 | 7 | 2.2 | 3 | 3 | 2 |
| Initial symptom(s) | Falls & cognitive slowing | Falls & cognitive slowing | Falls | Slow up | Slurred speech | Balance difficulty | Falls | Falls | Falls |
| Asymmetrical features | – | – | – | – | – | – | – | – | – | – |
| Limb apraxia | – | – | – | – | – | – | – | – | – | – |
| Alien limb | – | – | – | – | – | – | – | – | – | – |
| Cortical sensory loss | – | – | – | – | – | – | – | – | – | – |
| Hemineglect | – | – | – | – | – | – | – | – | – | – |
| Aphasia | – | – | – | – | – | – | – | – | – | – |
| Hand dystonia | – | – | – | – | – | – | – | – | – | – |
| Clenched fist | – | – | – | – | – | – | – | – | – | – |
| Myoclonus | – | – | – | – | – | – | – | – | – | – |
| Tremor | + | – | – | – | – | – | – | – | – | + |
| Delayed initiation of saccades | NK | – | – | NK | – | – | – | – | – | NK |
| Slow vertical saccades | + | NK | + | NK | + | + | NK | + | + | NK |
| VSGP | + | + | + | + | + | + | + | + | + | + |
| Postural instability/falls within 1st yr | + | + | + | + | + | + | + | + | + | + |
| Cognitive decline | + | – | – | – | – | – | – | – | – | – |
| Personality change/apathy | + | + | + | + | + | + | + | + | + | + |
| Pyramidal signs | – | – | – | – | – | – | – | – | – | – |
| Early akinetic rigidity in first 2 yrs | + | + | + | + | + | + | + | + | + | + |
| Early dysarthria in first 2 yrs | + | NK | – | – | – | – | – | – | NK | + | – |
| Early dysphagia in first 2 yrs | + | – | – | – | – | – | – | – | NK | + | – |
| Levodopa response | – | – | – | – | – | – | – | – | – | – |
| H1/H2 Haplotype | H1/H1 | H1/H1 | NK | H1/H1 | H1/H1 | H1/H1 | H1/H1 | H1/H1 | H1/H1 | H1/H1 |

CBS, corticobasal syndrome; C.Spond, cervical spondylosis; CVD, cerebrovascular disease; Dx, diagnosis; F, female; M, male; NA, not applicable; NK, not known; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; RS, Richardson’s syndrome; VSGP, vertical supranuclear gaze palsy; yr, year.
cases these occurred in the advanced stage of the illness. Two exceptions were cases 8 and 9 who developed VSGP within 4 years from symptom onset and an initial clinical diagnosis of PSP was considered, but was later revised to CBS after the onset of asymmetrical cortical symptoms. Six patients developed postural instability or falls within the first year of symptom onset. Nevertheless, VSGP (χ², \( P = 0.016 \)) and postural instability or early falls were still more frequent in PSP-RS than in PSP-CBS. Pyramidal signs were more frequent in PSP-CBS (\( n = 5 \)) than in PSP-RS (\( n = 0 \)) (χ², \( P = 0.016 \)). Extensor plantars and hyperreflexia were noted in five PSP-CBS patients, three of whom also had spasticity and one had pyramidal weakness, but none of these features was observed in PSP-RS.

**PSP-RS (Tables 1b and 2)**  All PSP-RS patients had a final clinical diagnosis of probable PSP and had VSGP including downgaze abnormalities and early postural instability or falls. Three patients had cognitive decline and five had frontal type personality change characterized by apathy and abulia.

**Pathological findings and clinicopathological correlations**

Both PSP-CBS and PSP-RS groups met established pathological criteria of PSP [20–22]. All inclusion types were immunoreactive for 4R tau by differential immunohistochemistry but negative for 3R tau in all cases [24], which was an expected finding for PSP.

‘Regional’ tau load  The median ‘regional’ tau load in the posterior frontal cortical grey matter (PSP-CBS: 0.59; PSP-RS: 0.05), anterior frontal cortical grey matter (PSP-CBS: 0.06; PSP-RS: 0.03) and parietal subcortical white matter (PSP-CBS: 0.06; PSP-RS: 0.01) was significantly greater in PSP-CBS than in PSP-RS (\( P < 0.003 \) in all). The median ‘regional’ tau load in the caudate (PSP-CBS: 0.14; PSP-RS: 0.49; \( P < 0.001 \)), STN (PSP-CBS: 0.21; PSP-RS: 0.40; \( P < 0.001 \)) and cerebellar white matter (PSP-CBS: 0.02; PSP-RS: 0.06; \( P = 0.007 \) with borderline significance) was greater in the PSP-RS than in PSP-CBS (Figures 1 and 2).

The presence of delayed initiation of horizontal saccades in PSP-CBS had a moderate correlation with an increased total parietal ‘tau load’ (Spearman’s correlation coefficient = 0.59; \( P < 0.001 \)). However, other cortical features such as cortical sensory loss, alien limb phenomenon or hemi-sensory neglect did not correlate with the parietal ‘tau load’ (\( P > 0.05 \)) or other ‘regional tau load’.

**Table 2.** Demographic features between PSP-CBS and PSP-RS

|                | PSP-CBS | PSP-RS | \( P \) values (Student’s \( t \)-test) |
|----------------|---------|--------|----------------------------------------|
| Mean age of symptom onset (mean years ± SD) | 65.9 ± 8.0 | 65.9 ± 7.1 | 0.98 |
| Mean age of death (mean years ± SD) | 73.4 ± 6.4 | 74.4 ± 6.5 | 0.72 |
| Mean disease duration (mean years ± SD) | 7.5 ± 2.7 | 8.6 ± 4.4 | 0.51 |

*Regional* tau load in the caudate (PSP-CBS: 0.14; PSP-RS: 0.49; \( P < 0.001 \)), STN (PSP-CBS: 0.21; PSP-RS: 0.40; \( P < 0.001 \)) and cerebellar white matter (PSP-CBS: 0.02; PSP-RS: 0.06; \( P = 0.007 \) with borderline significance) was greater in the PSP-RS than in PSP-CBS (Figures 1 and 2). In five PSP-CBS cases, the half brains examined were contralateral to the side with the more predominant clinical symptoms and signs. The median ‘total’ and ‘cortical’ tau load were numerically, but not statistically, greater in these five cases (total tau load = 5.3; cortical tau...
Figure 2. Tau immunohistochemistry in selected brain regions of the two most representative cases. PSP-CBS has significantly greater tau load in the posterior frontal (A) and anterior frontal grey matter (C) when compared with PSP-RS (B, D). Regional tau load in the caudate and subthalamic nucleus are greater in PSP-RS (F, H) than in PSP-CBS (E, G). Median tau load values. Posterior frontal grey matter: (A) PSP-CBS: 1.09; (B) PSP-RS: 0.05; Anterior frontal grey matter: (C) PSP-CBS: 0.18; (D) PSP-RS: 0.04; Caudate: (E) PSP-CBS: 0.11; (F) PSP-RS: 1.06; Subthalamic nucleus: (G) PSP-CBS: 0.05; (H) PSP-RS: 0.29. Tau load for each region, that is, 'regional' tau load was expressed as percentage (areal fraction × 100%): 'areal fraction', which was computed by Image Pro, was defined by a ratio of the tau-positive immunoreactive pixels to the total number of pixels of the whole field. AT8 immunohistochemistry, bar in panel B represents 225 microns in all the panels.
load = 1.4) compared with the remaining PSP-CBS cases (total tau load = 4.0; cortical tau load = 1.0).

**Tau-positive cellular lesions** In the posterior frontal cortical grey matter, all types of tau lesions were more numerous in PSP-CBS than in PSP-RS (NFTs, TAs, CBs and NTs: \( P < 0.001 \); PreTs: \( P = 0.005 \)). In the anterior frontal grey matter, there were numerically, but not statistically, more NFTs, CBs and NTs in PSP-CBS than in PSP-RS (\( P > 0.01 \) in all). In the caudate, there were more TAs, NTs, and NFTs, in PSP-RS than in PSP-CBS (TAs and NTs: \( P < 0.001 \), NFTs: \( P = 0.01 \)).

**Neuronal loss** In the STN, the median semi-quantitative rating score for neuronal loss was moderate (grade 2) and there was no difference between the two groups (\( \chi^2; P \geq 0.05 \)). In the SN, neuronal loss was more severe in the dorsolateral (\( \chi^2; P = 0.033 \)) and ventrolateral (\( \chi^2; P = 0.018 \)) subregions in PSP-RS than in PSP-CBS (Figure 4).

**CST involvement** There was a more severe microglial response in the CST in PSP-CBS, ranged from mild to severe, than in PSP-RS, in which CST involvement was very mild (\( \chi^2; P = 0.035 \)) (Figure 5).

**Additional pathological findings** The CERAD Aβ plaque score ranged from ‘absent’ to ‘sparse’, except for two PSP-CBS and one PSP-RS cases, which had a ‘moderate’ score [27]. Small vessel cerebrovascular disease was noted in one PSP-CBS and one PSP-RS case. Other additional pathological findings are summarized in Table 3.

**Tau biochemistry and haplotype analysis** Western blots of the sarkosyl-insoluble tau fractions from the frontal cortical homogenates showed the characteristic doublet at 64 and 68 kDa indicating predominant 4R tau in PSP-CBS, PSP-RS and CBD-CBS cases (Figure 6). Our PSP-CBS and PSP-RS cases showed a single band at approximately 33 kDa, whereas the CBD-CBS cases had a doublet at approximately 37 kDa (Figure 6), which are consistent with previous findings on the molecular differences in the low molecular weight proteolytic fragments between CBD and PSP [14,40]. There was no significant association between H1/H1 or H1/H2 genotype with either of the PSP subgroups (\( \chi^2 \) test; \( P = 0.21 \), Table 1).
We compared the morphological, biochemical and genetic characteristics of 10 clinically well-characterized PSP-CBS cases and 10 age- and disease duration-matched PSP-RS controls. Irrespective of the clinical presentation, all our cases met established neuropathological diagnostic criteria of PSP with the presence of 4R tau-positive neuronal and glial inclusions, including TAs in a characteristic distribution [20–22]. Our biochemical studies of sarcosyl insoluble tau also confirmed 4R tau as the main protein species in both PSP-RS and PSP-CBS groups and the presence of a smaller, faster migrating carboxy-terminal fragment as previously reported in PSP [40,41]. We found no difference in the distribution of the H1/H1 and H1/H2 haplotypes between the two PSP groups.

We used morphometry to compare tau load, defined as the sum of all tau positive lesions in the brain regions studied, between the two PSP groups and to determine the contribution of different neuronal and glial lesions to the tau pathology. A previous study at the Mayo Clinic established that PSP-CBS was associated with a greater tau burden in the mid-frontal and inferior-parietal corti-
ces than in PSP-RS [12]. Here, by assessing a greater number of cases and more brain regions, we validated their findings by showing increased tau load in the cortical regions predominantly in the posterior frontal grey matter, anterior frontal grey matter and parietal white matter in PSP-CBS. We also extended the quantitative tau assessment to other non-cortical regions which enabled us to identify a reduced tau load in the caudate, STN and cerebellar white matter in the CBS variant. It is noteworthy that the increased cortical tau load is compensated by the reduced basal ganglia tau load in PSP-CBS resulting in the total tau load, determined as the sum of the all regional tau load, being similar in the two PSP groups.

Increased cortical tau pathology has also been documented in PSP variants with cortical features including ‘atypical’ PSP with progressive apraxia of speech and non-fluent aphasia [42]. PSP-bvFTD [11,43], and, together with PSP-CBS, these clinical phenotypes are collectively referred as the ‘cortical’ PSP variants [44]. On the other hand, PSP-P and PSP-PAGF, which are considered as the ‘brainstem’ variants of PSP, have less severe overall tau pathology when compared with PSP-RS [5,6]. Interestingly, these ‘brainstem’ variants are associated with a more benign disease course and a longer disease duration compared with the classical PSP-RS [5,6,30]; whereas the disease duration of our PSP-CBS group was similar to that of PSP-RS group previously reported [2]. We speculate that the total tau pathology may inversely correlate with the disease duration in PSP variants and while the ‘brainstem’ PSP variant appears to be a more ‘benign’ form of PSP, the ‘cortical’ PSP variant represents a deviation from the classical presentation determined by a shift of tau pathology from the basal ganglia to the cerebral cortex. By selecting only cases with limited Alzheimer-type NFT pathology and assessing coexisting secondary pathologies, it is clear that the clinical presentation in our PSP-CBS cases was closely associated with the topographical severity of tau pathology which could not otherwise be explained by secondary pathologies. We also demonstrated that the regional differences in tau load between the two PSP groups were contributed by neuronal and glial lesions characteristic of PSP pathology rather than Alzheimer-related tau pathology [45].

A recent detailed clinicopathological study from the Mayo Clinic compared the characteristics of CBS and RS clinical phenotypes in pathologically confirmed CBD cases [14]. Their study on CBD also demonstrated significant differences in the topographical severity of tau pathology between the two CBD subtypes, which correlated with the different clinical presentations. Similar to the findings in our PSP-CBS cases, their study showed that the CBD-CBS cases had more severe tau deposition in the cortical regions and less severe tau pathology in the lower brainstem and cerebellum when compared with the CBD-RS cases. However, total tau load and the contribution by different neuronal and glial lesions to the tau pathology were not assessed [14].

The STN is one of the regions characteristically targeted by the PSP disease process [20,46] while this nucleus is better preserved in cases with pathologically confirmed CBD. In our PSP-CBS cases, the atrophy and neuronal loss in the STN was as severe as in the PSP-RS cases, despite the regional tau load of the STN being less in PSP-CBS than in PSP-RS, indicating that glial, rather than neuronal tau, might have significantly contributed to the differences in tau load. It is noteworthy that a relatively milder tau pathology in the STN has been documented in other PSP variants such as ‘atypical’ PSP with progressive apraxia of speech and non-fluent aphasia [42].

In PSP, cell loss in the SN affects both the pigmented neurones of the pars compacta and non-pigmented neurones in the pars reticulata, whereas neurones in the medial nigra are relatively preserved [47]. In the present study, neuronal loss was less severe in the ventrolateral and dorsolateral subregions in PSP-CBS when compared with PSP-RS (Figure 4). This regional difference may, in part, influence the clinical features due to the resulting selective damage to the dopaminergic and GABAergic neuronal nigral projections [47].

Pyramidal signs were documented in half of our PSP-CBS cases, but they were absent in our PSP-RS cohort. Pyramidal signs are relatively uncommon in PSP and in one series they were present in only one fifth of all pathologically confirmed PSP cases [2]. On the other hand, 60% of pathologically confirmed CBD cases had pyramidal signs [48]. In CBD, the pathological involvement of the primary motor cortex including loss of Betz cells is a common finding, explaining the presence of pyramidal signs [44,48]. The common occurrence of pyramidal signs in our PSP-CBS cohort can be explained by the abundant tau pathology in the primary motor cortex, which was 12-fold greater in PSP-CBS than in PSP-RS. There was also more severe microglial pathology in the CST in PSP-CBS than in PSP-RS. CST degeneration and significant tau pathology in the motor cortex are also prominent in a group of ‘atypical’ PSP cases reported in the literature which sometimes clini-
cally present with CBS [44,49]; however, whether these cases should be classified as PSP has recently been questioned [50].

All PSP-CBS cases had received a final clinical diagnosis of CBS and they all had markedly asymmetrical cortical and extrapyramidal features, including unilateral limb clumsiness with a progressively maladroit and functionally useless hand. In the past, the presence of marked asymmetrical clinical signs would exclude the clinical diagnosis of PSP, but this concept has been challenged in recent years with the findings of clinicopathological series confirming asymmetrical presentations in some PSP variants [2,17]. Previously, a post mortem report of a Japanese patient who had focal limb dystonia and levitation revealed significantly more tau pathologies in the frontal cortices, basal ganglia and brain stem in the contralateral half brain than the ipsilateral half brain [51]. In our PSP-CBS cohort, there was numerically greater total tau load and cortical tau load in five cases where the contralateral half brain was available for evaluation when compared with the other five cases where ipsilateral half brain was examined. However, we cannot conclude if the tau load is greater in the clinically more manifested hemisphere within an individual as only half brains were used. Asymmetrical limb apraxia and delayed initiation of horizontal saccades are clinical features suggestive of underlying parietal lobe dysfunction and are characteristic features of CBS [52]. We found that regional tau load in the parietal white matter was 5-fold greater in PSP-CBS than in PSP-RS and that PSP-CBS patients who had delayed initiation of horizontal saccades also had greater regional tau load in the parietal cortex and white matter.

Three patients had delayed initiation of horizontal saccades and, interestingly, half of them also had VSGP in the late stage of the illness, with involvement of downgaze, a diagnostic prerequisite for the diagnosis of PSP-RS [53,54]. VSGP is rare in CBD with classical CBS presentation (CBD-CBS), and was noted in only 18% of cases in the Mayo Clinic series [14] and was not observed in the QSBB series [17]. Six PSP-CBS patients had recurrent falls in the first year of their illness, whereas early falls were less frequent in CBD-CBS cases and were recorded in only 20% and 18% in the QSBB and Mayo Clinic series, respectively [14,17]. We postulate that early postural instability, falls and supranuclear downgaze palsy in patients with CBS are clinical clues which when present, suggest an underlying PSP pathology even though there are also signs of CBS. Nevertheless, three cases in our PSP-CBS group (cases 2, 7, 10) had a pure CBS presentation throughout the disease course and did not have any tell-tale signs of PSP. This is in concordance with our experience based on clinicopathological evaluation of cases in the QSBB that some pathologically confirmed PSP and CBD cases present with a pure clinical syndrome such as CBS or RS irrespective of the underlying pathology, whereas some cases manifest overlap clinical features such as RS or CBS at the same time and occasionally, the clinical syndromes temporally evolve from one to another throughout the disease course as previously described by Kertesz et al. [9].

Data from transgenic animal studies indicate that soluble rather than fully aggregated tau species may ultimately be responsible for neuronal degeneration and cell death [55]. However, the findings in this study support the notion that neuronal and glial inclusions composed of fibrillar pathological tau are useful and clinically valid pathological markers of the underlying neurodegenerative process. We have provided comprehensive evidence that the topographical severity of tau pathology in PSP is closely associated with its clinical manifestation [5,6,11,30,42]. This is comparable to the findings in Alzheimer’s disease where cognitive deficit shows a far better correlation with tau lesions than with Aβ plaques [56] as well as in other primary tauopathies [44,57]. A better understanding of the factors that influence the selective pathological vulnerability in different PSP variants will provide further insights into the neurodegenerative process underlying tauopathies.

Acknowledgements

H. L. presented this work at the British Neuropathological Society Annual Meeting in January 2012. The authors would like to thank all patients and their families for their support of this research. We would also like to thank Linda Parsons and Kate Strand for their help with tissue preparation, data retrieval and technical support, and Zoe Fox for her statistical advice.

Funding

H. L. is supported by the PSP Association research grant (6AMN) and is employed by the Reta Lila Weston Trust for Medical Research, University College London. L. A. M. has been supported by a grant from the PSP (Europe) Association. J. L. H. is supported by the Reta Lila Weston Institute
for Neurological Studies. T. R. and J. L. H. are supported by research grants from Alzheimer’s Research UK, Parkinson’s UK and the Multiple System Atrophy Trust. N. B. is supported by research grants from the MRC and Parkinson’s UK. This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. The research was partly supported by the National Institute for Health Research (NIHR) Biomedical Research Unit in Dementia based at University College London Hospitals (UCLH), University College London (UCL). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Authors’ roles

1. Research project: A, Conception; B, Organization; C, Execution.
2. Statistical analysis: A, Design; B, Execution; C, Review and Critique.
3. Manuscript: A, Writing of the first draft; B, Review and Critique.

References

1 Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333–59
2 Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005; 128: 1247–58
3 Williams DR, Lees AJ, Wherrett JR, Steele JC. J. Clifford Richardson and 50 years of progressive supranuclear palsy. Neurology 2008; 70: 566–73
4 Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord 2010; 25: 357–62
5 Ahmed Z, Josephs KA, Gonzalez J, DelleDonne A, Dickson DW. Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy. Brain 2008; 131: 460–72
6 Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22: 2235–41
7 Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, Kril JJ, Halliday GM. Clinico-pathological correlates in frontotemporal dementia. Ann Neurol 2004; 56: 399–406
8 Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, Hauser MF, Witte RJ, Boeve BF, Knopman DS, Dickson DW, Jack CR Jr, Petersen RC. Clinico-pathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129: 1385–98
9 Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 2005; 128: 1996–2005
10 Hu WT, Parisi JE, Knopman DS, Boeve BF, Dickson DW, Ahlskog JE, Petersen RC, Josephs KA. Clinical features and survival of 3R and 4R tauopathies presenting as behavioral variant frontotemporal dementia. Alzheimer Dis Assoc Disord 2007; 21: S39–43
11 Hassan A, Parisi JE, Josephs KA. Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia. Neurocase 2012; 18: 478–88
12 Tsuibo Y, Josephs KA, Boeve BF, Litvan I, Caselli RJ, Caviness JN, Uitti RJ, Bitt AD, Dickson DW. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord 2005; 20: 982–8
13 Bigio EH, Vono MB, Satumtria S, Adamson J, Songt E, Hynan LS, White CL 3rd, Baker M, Hutton M. Cortical synapse loss in progressive supranuclear palsy. J Neuropathol Exp Neurol 2001; 60: 403–10
14 Kouri N, Murray ME, Hassan A, Rademakers R, Uitti RJ, Boeve BF, Graff-Radford NR, Wszolek ZK, Litvan I, Josephs KA, Dickson DW. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 2011; 134 (Pt 11): 3264–75
15 Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112 (Pt 5): 1171–92
16 Rebeiz JJ, Kolody EH, Richardson EP Jr. Corticodentatorigial degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 1967; 92: 23–6
17 Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, Paviour DC, Lees AJ. Does corticobasal degeneration exist? A clinico-pathological re-evaluation. Brain 2010; 133: 2045–57
18 Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR. Focal cortical presentations of Alzheimer’s disease. *Brain* 2007; 130: 2636–45
19 Whitwell JL, Jack CR Jr, Boeve BF, Parisi JE, Ahskog JE, Drubach DA, Senjem ML, Knopman DS, Petersen RC, Dickson DW, Josephs KA. Imaging correlates of pathology in corticobasal syndrome. *Neurology* 2010; 75: 1879–87
20 Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). *Neurology* 1994; 44: 2015–19
21 Ince PG, Clark B, Holton JL, Revesz T, Wharton S. Disorders of movement and system degenerations. In *Greenfield’s Neuropathology* 8th edn. Eds S Love, DN Louis, DW Ellision. London: Arnold, 2008; 889–1030
22 Dickson D, Hauw JJ, Agid Y, Litvan I. Progressive supranuclear palsy and corticobasal degeneration. In *Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders*, Eds D Dickson, RO Weller. West Sussex, UK: Wiley-Blackwell, 2011; 135–55
23 Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, McKee A, Dickson D, Bancher C, Tabaton M, Jellinger K, Anderson DW. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. *J Neuropathol Exp Neurol* 1996; 55: 97–105
24 de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, Bandopadhyay R, Uton M, Strand C, Jowett T, Khan N, Anderton B, Wood N, Holton J, Revesz T, Lees A. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. *Neuropathol Appl Neurobiol* 2003; 29: 288–302
25 Brestaft J, Lashley T, Holton JL, Lees AJ, Rossor MN, Bandopadhyay R, Revesz T, Transportin1: a marker of FTD-FUS. *Acta Neuropathol* 2011; 122: 591–600
26 Togo T, Sahara N, Yen SH, Cookson N, Ishizawa T, Hutton M, de Silva R, Lees A, Dickson DW. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. *J Neuropathol Exp Neurol* 2002; 61: 547–56
27 Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. *Neurology* 1991; 41: 479–86
28 Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol* 2006; 112: 389–404
29 Compta Y, Parkkinen L, O’Sullivan SS, Vandervcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? *Brain* 2011; 134: 1493–505
30 Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, Revesz T. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. *Brain* 2007; 130: 1566–76
31 Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. *J Neuropathol Exp Neurol* 2003; 62: 885–98
32 Sundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, West MJ. Some new, simple and efficient stereological methods and their use in pathologi- cal research and diagnosis. *APMIS* 1988; 96: 379–94
33 Puig B, Rey MJ, Ferrer I. Individual and regional variations of phospho-tau species in progressive supranuclear palsy. *Acta Neuropathol* 2005; 110: 261–8
34 Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isofoms. *Neuron* 1992; 8: 159–68
35 Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. *Proc Natl Acad Sci USA* 1990; 87: 5827–31
36 Cairns NJ, Atkinson PF, Hanger DP, Anderton BH, Daniel SE, Lantos PL. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer’s disease. *Neurosci Lett* 1997; 230: 49–52
37 Brion JP, Couch AM, Robertson J, Loviny TL, Anderton BH. Neurofilament monoclonal antibodies RT97 and 8D8 recognize different modified epitopes in paired helical filament-tau in Alzheimer’s disease. *J Neurochem* 1993; 60: 1372–82
38 Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. *Hum Mol Genet* 1999; 8: 711–15
39 Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandervcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Muller U, Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nat Genet* 2011; 43: 699–705
40 Arai T, Ikeda K, Akiyama H, Shikamoto Y, Tsuchiya K, Yagishita S, Beach T, Rogers J, Schwab C, McGeer PL.
Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, corticobasal degeneration and progressive supranuclear palsy. 

*Acta Neuropathol* 2001; 101: 167–73

41 Wray S, Saxton M, Anderton BH, Hanger DP. Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. 

*J Neurochem* 2008; 105: 2343–52

42 Josephs KA, Boeve BF, Duffy JR, Smith GE, Knopman DS, Parisi JE, Petersen RC, Dickson DW. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. 

*Neurocase* 2005; 11: 283–96

43 Hu WT, Parisi JE, Knopman DS, Boeve BF, Dickson DW, Ahlskog JE, Petersen RC, Josephs KA. Clinical features and survival of 3R and 4R tauopathies presenting as behavioral variant frontotemporal dementia. 

*Alzheimer Dis Assoc Disord* 2007; 21: S39–43

44 Dickson DW, Ahmed Z, Algoma AA, Tsuboi Y, Josep hs KA. Neuropathology of variants of progressive supranuclear palsy. 

*Curr Opin Neurol* 2010; 23: 394–400

45 Oshima K, Dickson DW. Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy. 

*Int J Clin Exp Pathol* 2009; 2: 399–406

46 Hardman CD, Halliday GM, McRitchie DA, Morris JG. The subthalamic nucleus in Parkinson’s disease and progressive supranuclear palsy. 

*J Neuropath Exp Neurol* 1997; 56: 132–42

47 Oyanagi K, Tsuchiya K, Yamazaki M, Ikeda K. Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features. 

*J Neuropath Exp Neurol* 2001; 60: 393–402

48 Tsuchiya K, Murayama S, Mitani K, Oda T, Arima K, Mimura M, Nagura H, Haga C, Akiyama H, Yamanouchi H, Mizusawa H. Constant and severe involvement of Betz cells in corticobasal degeneration is not consistent with pyramidal signs: a clinicopathological study of ten autopsy cases. 

*Acta Neuropathol* 2005; 109: 353–66

49 Josephs KA, Katsuse O, Beccano-Kelly DA, Lin WL, Uitti RJ, Fujino Y, Boeve BF, Hutton ML, Baker MC, Dickson DW. Atypical progressive supranuclear palsy with corticospinal tract degeneration. 

*J Neuropath Exp Neurol* 2006; 65: 396–405

50 Ahmed Z, Doherty KM, Silveira-Moriyama L, Bandopadhyay R, Lashley T, Mamiis A, Hondhamumi G, Wray S, Newcombe J, O’Sullivan SS, Wroe S, de Silva R, Holton JL, Lees AJ, Revesz T. Globular glial tauopathies (GTT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. 

*Acta Neuropathol* 2011; 122: 415–28

51 Oide T, Ohara S, Yazawa M, Inoue K, Itoh N, Tokuda T, Ikeda S. Progressive supranuclear palsy with asymmetric tau pathology presenting with unilateral limb dystonia. 

*Acta Neuropathol* 2002; 104: 209–14

52 Vidailhet M, Rivaud-Pechoux S, Rivaud S, Gouider-Khouja N, Pillon B, Bonnet AM, Garmy B, Agid Y, Pierrot-Deseiligny C. Eye movement disorders in corticobasal degeneration. Eye movements in parkinsonian syndromes. 

*Adv Neurol* 2000; 82: 161–7

53 Lees AJ. The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). In: *Movement Disorders*. Eds CD Marsden, S Fahn. London: Butterworth-Heinemann, 1987; 272–87

54 Rivaud-Pechoux S, Vidailhet M, Gallouedec G, Litvan I, Garmy B, Pierrot-Deseiligny C. Longitudinal oculomotor study in corticobasal degeneration and progressive supranuclear palsy. 

*Neurology* 2000; 54: 1029–32

55 Kim HJ, Jeon BS, Lee JY, Yun JY. Survival of Korean patients with multiple system atrophy. 

*Mov Disord* 2011; 26: 909–12

56 Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. 

*Arch Neurol* 2004; 61: 378–84

57 Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R, Caselli RJ, Knopman DS, Petersen RC. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. 

*Neurology* 2004; 63: 1168–74

**Received 18 January 2013**

**Accepted after revision 15 February 2013**

**Published online Article Accepted on 22 February 2013**